ERBB2 and breast cancer: Selective HDAC inhibitors like Chidamide and Zabadinostat are being used in trials in combination with other anticancer drugs for treating HR-positive/HER2-negative BC and refractory HCC, respectively (NCT05873244, NCT05400993).